Key Takeaways
- • McGill University's D2R initiative is hosting an educational seminar on venture capital investment principles, featuring Inès Holzbaur, Founder and Managing Partner of AmorChem, an early-stage life science fund.
- • The seminar addresses a critical gap in academic-to-commercial translation: billions in annual research funding exist, yet the pathway from lab discovery to venture capital investment remains poorly understood by most researchers.
- • Holzbaur brings extensive transaction experience with major pharmaceutical players including Hoffman LaRoche and Vertex Pharmaceuticals, and co-founded NuChem Sciences, which she chaired from 2011–2019.
- • The session will provide practitioners with a framework for evaluating translational value of scientific opportunities, identifying criteria that distinguish fundable research from academic work, and understanding venture capitalist investment decision-making processes.
- • Event is accessible via dual attendance model (in-person at D2R offices in Montreal or virtual via Zoom), expanding access for institutional investors, biotech entrepreneurs, and life science professionals.
Summary
McGill University's DNA to RNA (D2R) initiative is convening an investor education seminar titled "Venture Capital Demystified," delivering insider perspectives on how early-stage life science investments are evaluated and structured. The seminar addresses a fundamental disconnect in the biotech ecosystem: while funding agencies deploy billions annually into basic and translational research, the mechanics of transitioning academic discoveries into venture-backed commercial entities remain opaque to most researchers and emerging entrepreneurs.
Inès Holzbaur, the featured speaker, brings credibility as Founder and Managing Partner of AmorChem, an early-stage life science fund where she developed an innovative investment model and established operational and investment processes. Her track record includes active involvement in significant pharmaceutical transactions with Hoffman LaRoche and Vertex Pharmaceuticals. Holzbaur also serves as Chair of NuChem Sciences from 2011–2019, further validating her expertise in translating scientific discovery into viable commercial ventures.
The seminar's stated objective is to provide attendees with clarity on venture capitalist decision frameworks, the characteristics that distinguish fundable research ideas from academic work, and the methodology investors deploy when assessing translational value of scientific opportunities. By session conclusion, participants will possess a practical framework for converting laboratory discoveries or mechanisms into investment-ready opportunities—a critical capability gap for academic researchers seeking commercialization pathways.
The D2R initiative, bolstered by Holzbaur's recent appointment to its Investment and Commercialization Committee, reflects McGill's commitment to bridging the academic-venture capital divide. Holzbaur's concurrent service as Vice-Chair of the Board of both the Quebec Biotechnology Innovation Centre and Génome Québec, combined with her involvement in Montreal InVivo initiatives, positions her as a central figure in Canada's early-stage life science ecosystem.
The hybrid delivery model—offering both in-person attendance at D2R offices (1010 Sherbrooke St. West, Suite 1800, Montreal) and virtual participation via Zoom—ensures accessibility for institutional investors, family offices, biotech entrepreneurs, and alternative investment professionals seeking to understand contemporary venture capital evaluation criteria in the life sciences sector.
Inès Holzbaur, the featured speaker, brings credibility as Founder and Managing Partner of AmorChem, an early-stage life science fund where she developed an innovative investment model and established operational and investment processes. Her track record includes active involvement in significant pharmaceutical transactions with Hoffman LaRoche and Vertex Pharmaceuticals. Holzbaur also serves as Chair of NuChem Sciences from 2011–2019, further validating her expertise in translating scientific discovery into viable commercial ventures.
The seminar's stated objective is to provide attendees with clarity on venture capitalist decision frameworks, the characteristics that distinguish fundable research ideas from academic work, and the methodology investors deploy when assessing translational value of scientific opportunities. By session conclusion, participants will possess a practical framework for converting laboratory discoveries or mechanisms into investment-ready opportunities—a critical capability gap for academic researchers seeking commercialization pathways.
The D2R initiative, bolstered by Holzbaur's recent appointment to its Investment and Commercialization Committee, reflects McGill's commitment to bridging the academic-venture capital divide. Holzbaur's concurrent service as Vice-Chair of the Board of both the Quebec Biotechnology Innovation Centre and Génome Québec, combined with her involvement in Montreal InVivo initiatives, positions her as a central figure in Canada's early-stage life science ecosystem.
The hybrid delivery model—offering both in-person attendance at D2R offices (1010 Sherbrooke St. West, Suite 1800, Montreal) and virtual participation via Zoom—ensures accessibility for institutional investors, family offices, biotech entrepreneurs, and alternative investment professionals seeking to understand contemporary venture capital evaluation criteria in the life sciences sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.